Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Show more

Location: 100 Campus Drive, Florham Park, NJ, 07932, United States | Website: https://www.phathompharma.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

640.9M

52 Wk Range

$2.21 - $19.71

Previous Close

$9.18

Open

$9.09

Volume

542,343

Day Range

$8.81 - $9.34

Enterprise Value

1.022B

Cash

212.3M

Avg Qtr Burn

-70.67M

Insider Ownership

4.28%

Institutional Own.

84.72%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
VOQUEZNA (Vonoprazan) (Potassium competitive acid blocker) Details Bacterial infection	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VOQUEZNA (Vonoprazan)(Potassium competitive acid blocker) Details Intestinal infection, Gastroesophageal reflux disease, Esophagitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VOQUEZNA® (vonoprazan)(potassium competitive acid blocker) Details Gastroesophageal reflux disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VOQUEZNA® (vonoprazan)(potassium competitive acid blocker) Details Gastroesophageal reflux disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VOQUEZNA® (Vonoprazan)(potassium competitive acid blocker) Details Eosinophilic Esophagitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.